Ximoprofen

CAS No. 56187-89-4

Ximoprofen( —— )

Catalog No. M34737 CAS No. 56187-89-4

Ximoprofen is a novel anti-inflammatory compound for the study of spondylitis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 851 In Stock
10MG 1169 In Stock
25MG 1729 In Stock
50MG 2279 In Stock
100MG 3060 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Ximoprofen
  • Note
    Research use only, not for human use.
  • Brief Description
    Ximoprofen is a novel anti-inflammatory compound for the study of spondylitis.
  • Description
    Ximoprofen is a novel anti-inflammatory compound for the study of spondylitis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    56187-89-4
  • Formula Weight
    261.32
  • Molecular Formula
    C15H19NO3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N(O)=C1CC(C2=CC=C(C(C(O)=O)C)C=C2)CCC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • DS-1040 tosylate hyd...

    DS-1040 tosylate hydrate (DS1040) is a small molecule inhibitor of the activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50 of 1.7 ng/mL for rabbit TAFIa.

  • Kisspeptin-13 (human...

    Kisspeptin 13 inhibits glucose-induced insulin secretion with an IC50 of 1.2 nM. Kisspeptin 13 activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research.

  • Melrilimab

    Melrilimab (GSK 3772847), an IgG2-kappa monoclonal antibody targeting IL1RL1/ST2/IL33R/DER4/FIT-1, is utilized in asthma research .